068270.KS
Celltrion, Inc.
KSC · Healthcare · Biotechnology · KR
KRW 187,100.00
+0.43%Year over year
Reported trailing growth
- Revenue
- +30.6%
- EBITDA
- +38.0%
- EBIT
- +94.2%
- EPS
- +207.4%
- Free cash flow
- +20.0%
- Operating cash flow
- +8.0%
Forward estimates
Based on analyst estimates
- Revenue
- +20.6%
- EBITDA
- +14.8%
- EPS
- -11.3%
Three-year CAGR
- Revenue
- +22.1%
- EBITDA
- +21.9%
- EBIT
- +21.8%
- Net income
- +24.2%
- EPS
- +4.7%
- Free cash flow
- +61.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026